Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Gibbons

Showing results (331-340 of 470) with videos related to

Pageof 47
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2024
YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic VulnerabilitiesC Allison Stewart, Lixia Diao, Yuanxin Xi, et al.
Cancer Letters|June 18, 2026
Deep Learning of CT Imaging Predicts PD-L1 Expression and Immunotherapy Response in Metastatic NSCLC: A Multi-Center StudyAmgad Muneer, Eman Showkatian, Maliazurina B Saad, et al.
Cancers|November 13, 2025
Radiomics for Dynamic Lung Cancer Risk Prediction in USPSTF-Ineligible PatientsMorteza Salehjahromi, Hui Li, Eman Showkatian, et al.
Nature Communications|October 29, 2014
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppressionLimo Chen, Don L Gibbons, Sangeeta Goswami, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2020
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancerKyle G Mitchell, Behrang Amini, Yunfei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2020
A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung CancerTina Cascone, Boris Sepesi, Heather Y Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2016
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung CancerVassiliki Papadimitrakopoulou, J Jack Lee, Ignacio I Wistuba, et al.
BMC Medicine|October 26, 2016
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation setJason Roszik, Lauren E Haydu, Kenneth R Hess, et al.
Nature Communications|August 20, 2021
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancerTina Cascone, Annikka Weissferdt, Myrna C B Godoy, et al.
Cancer Immunology Research|March 19, 2026
FOXM1-specific TCR-engineered T cells target non-small cell lung cancerEmily Bontekoe, Minying Zhang, Peixin Jiang, et al.
Pageof 47

Showing results (331-340 of 470) with videos related to

Sort By:
Pageof 47
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2024
YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic VulnerabilitiesC Allison Stewart, Lixia Diao, Yuanxin Xi, et al.
Cancer Letters|June 18, 2026
Deep Learning of CT Imaging Predicts PD-L1 Expression and Immunotherapy Response in Metastatic NSCLC: A Multi-Center StudyAmgad Muneer, Eman Showkatian, Maliazurina B Saad, et al.
Cancers|November 13, 2025
Radiomics for Dynamic Lung Cancer Risk Prediction in USPSTF-Ineligible PatientsMorteza Salehjahromi, Hui Li, Eman Showkatian, et al.
Nature Communications|October 29, 2014
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppressionLimo Chen, Don L Gibbons, Sangeeta Goswami, et al.
Cancer Immunology, Immunotherapy : CII|April 18, 2020
<sup>18</sup>F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancerKyle G Mitchell, Behrang Amini, Yunfei Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2020
A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung CancerTina Cascone, Boris Sepesi, Heather Y Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2016
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung CancerVassiliki Papadimitrakopoulou, J Jack Lee, Ignacio I Wistuba, et al.
BMC Medicine|October 26, 2016
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation setJason Roszik, Lauren E Haydu, Kenneth R Hess, et al.
Nature Communications|August 20, 2021
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancerTina Cascone, Annikka Weissferdt, Myrna C B Godoy, et al.
Cancer Immunology Research|March 19, 2026
FOXM1-specific TCR-engineered T cells target non-small cell lung cancerEmily Bontekoe, Minying Zhang, Peixin Jiang, et al.
Pageof 47